Study of Weekly Paclitaxel With Ramucirumab in Participants With Advanced Gastric Adenocarcinomas
2014年5月16日 更新者：Eli Lilly and Company
A Phase 1b Study of Weekly Paclitaxel With Ramucirumab (IMC-1121B) Drug Product in Patients With Advanced Gastric Adenocarcinomas
Investigate the safety and tolerability of ramucirumab (IMC-1121B) drug product (DP) in combination with paclitaxel.
調査の概要
研究の種類
介入
入学 (実際)
6
段階
- フェーズ 1
連絡先と場所
このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。
研究場所
-
-
-
Chiba、日本、277-8577
- ImClone Investigational Site
-
Osaka、日本、569-8686
- ImClone Investigational Site
-
Osaka、日本、589-5811
- ImClone Investigational Site
-
-
参加基準
研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。
適格基準
就学可能な年齢
20年歳以上 (大人、高齢者)
健康ボランティアの受け入れ
いいえ
受講資格のある性別
全て
説明
Inclusion Criteria:
- Has a histopathologically or cytologically confirmed diagnosis of gastric or gastroesophageal junction (GEJ) adenocarcinoma
- Has an advanced or metastatic solid gastric adenocarcinoma that has failed standard therapy
- Has resolution of all clinically significant toxic effects of prior therapy, surgery, treatment with an investigational agent or device, treatment monoclonal antibody or small molecule, and radiotherapy or chemotherapy.
- Has adequate organ function
- Eligible participants of reproductive potential (both sexes) agree to use adequate contraceptive methods (hormonal or barrier methods) during the study period and for 12 weeks after the last dose of study medication
Exclusion Criteria:
- Has undergone major surgery within 28 days prior to the study, or subcutaneous venous access device placement within 7 days prior to the study registration date
- Has elective or planned surgery to be conducted during the trial
- Has had treatment with an investigational agent or device, an antineoplastic small molecule, or antineoplastic radiotherapy or chemotherapy
- Was previously treated with a chemotherapy regimen containing nitrosoureas or mitomycin C
- Has had treatment with an antineoplastic monoclonal antibody within 8 weeks prior to the study registration date
- Has a history of deep vein thrombosis, pulmonary embolism, or any other significant thromboembolism prior to the study registration date
- Has experienced any arterial thrombotic event, including myocardial infarction, cerebrovascular accident, or transient ischemic attack, within 6 months prior to the study date
- Is receiving therapeutic anticoagulation with warfarin, low-molecular weight heparin or similar agents. (Participants receiving prophylactic, low-dose anticoagulation therapy are eligible provided that the coagulation parameters International Normalized Ratio (INR) ≤ 1.5, prothrombin time (PT) and partial thromboplastin time (PTT) or - Is receiving chronic therapy with nonsteroidal anti-inflammatory agents [Aspirin use at doses up to 325 milligrams/day (mg/day) is permitted]
- Has significant bleeding disorders, vasculitis, history of postoperative bleeding complications, hemoptysis or had a significant bleeding episode from the gastrointestinal (GI) tract within 3 months prior to the study date
- Has a history of GI perforation and/or fistulae within 6 months prior to the study date
- Has symptomatic congestive heart failure, unstable angina pectoris, or symptomatic or poorly controlled cardiac arrhythmia
- Has uncontrolled arterial hypertension despite standard medical management.
- Has a serious or nonhealing wound or peptic ulcer or bone fracture within 28 days prior to the study date
- Has a bowel obstruction, history or presence of inflammatory enteropathy or extensive intestinal resection, Crohn's disease, ulcerative colitis, or chronic diarrhea
- Has a serious illness or medical condition(s)
- Is pregnant or lactating
- Has received treatment with another investigational drug or participation in another interventional clinical trial within 28 days prior to the study date
研究計画
このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：処理
- 割り当て：なし
- 介入モデル：単一グループの割り当て
- マスキング：なし（オープンラベル）
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的：Ramucirumab (IMC-1121B ) and Pacitaxel
Each treatment cycle is 4 weeks (28 days)
|
8 milligrams/kilogram (mg/kg) intravenously on Days 1 and 15 of each 28-ay cycle
他の名前：
80 milligram/square meter (mg/m2) intravenously Days 1, 8, and 15 of each 28 day cycle
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Number of Participants With a Dose-Limiting Toxicity (DLT) During Cycle 1
時間枠：Cycle 1 of 28-day cycle
|
DLT based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCICTCAE v4.02) in Cycle (Cy) 1 due to study drug (SD) with (w/): Grade (Gr) ≥3 neutropenia w/fever ≥38.5°C or w/bacteremia or sepsis, thrombocytopenia w/bleeding and platelet substitution, prothrombin and/or partial thromboplastin time w/no anticoagulation, hyperbilirubinemia; Gr 4: neutropenia >5 days, thrombocytopenia, Gr 4 or uncontrollable hypertension QTc>500 milliseconds (ms) or increase ≥100 ms increase in 24 hours after SD or significant arrhythmia in this period; Gr ≥3 nonhematologic toxicity (tox), excluding Gr 3 hypersensitivity, hypertension, injection-site reaction, arthralgia/myalgia, asthenia/fatigue, diarrhea w/out loperamide/nausea/vomiting w/out antiemetic and transient aminotransferase elevation.
SD tox=delay >1 week in ramucirumab (RAM) dose or omission of 1 dose of RAM or 2 paclitaxel doses due to tox in Cy 1 or delay >2 weeks between Cy 1 and Cy 2 due to persistent tox.
|
Cycle 1 of 28-day cycle
|
|
Number of Participants With Adverse Events (AEs)
時間枠：Up to 47 weeks post baseline
|
The number of participants who experienced AEs of any grade, AEs of Grade ≥3 or AEs resulting in death that were considered to be related to ramucirumab [RAM (IMC-1121B)] or paclitaxel (PAC).
A summary of serious adverse events (SAEs) and all other non-SAEs, regardless of causality, is located in the Reported Adverse Events module.
|
Up to 47 weeks post baseline
|
|
Number of Participants With Serious Adverse Events (SAEs)
時間枠：Up to 47 weeks post baseline
|
The number of participants who experienced SAEs that were considered to be related to ramucirumab [RAM (IMC-1121B)] or paclitaxel (PAC).
A summary of SAEs and all other non-SAEs, regardless of causality, is located in the Reported Adverse Events module.
|
Up to 47 weeks post baseline
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Ramucirumab Maximum Serum Concentration (Cmax) for Cycle 1
時間枠：Cycle 1 Pre-infusion, Days 1, 2, 3, 5, 8, 12, and 15 of 28-day cycle
|
Cmax after a single dose of ramucirumab (IMC-1121B).
|
Cycle 1 Pre-infusion, Days 1, 2, 3, 5, 8, 12, and 15 of 28-day cycle
|
|
Serum Anti-Ramucirumab Antibody Assessment (Immunogenicity)
時間枠：Cycle 1 through Cycle 5 (28-day cycles)
|
The percentage of participants who were treatment-emergent positive for anti-ramucirumab (IMC-1121B) antibodies.
|
Cycle 1 through Cycle 5 (28-day cycles)
|
|
Ramucirumab Area Under the Concentration Time Curve (AUC) for Cycle 1
時間枠：Cycle 1 Pre-infusion, Days 1, 2, 3, 5, 8, 12, and 15 of 28-day cycle
|
AUC from time 0 to infinity (0-∞) after a single dose of ramucirumab (IMC-1121B).
|
Cycle 1 Pre-infusion, Days 1, 2, 3, 5, 8, 12, and 15 of 28-day cycle
|
|
Ramucirumab Half-Life (t1/2) for Cycle 1
時間枠：Cycle 1: Pre-infusion, Days 1, 2, 3, 5, 8, 12, and 15 of 28-day cycle
|
Terminal t1/2 (the time it takes for the concentration of ramucirumab (IMC-1121B) in plasma or serum to decline by 50%) after a single dose of ramucirumab (IMC-1121B).
|
Cycle 1: Pre-infusion, Days 1, 2, 3, 5, 8, 12, and 15 of 28-day cycle
|
|
Ramucirumab Clearance (CL) or Cycle 1
時間枠：Cycle 1: Pre-infusion, Days 1, 2, 3, 5, 8, 12, and 15 of 28-day cycle
|
CL [the volume of plasma or serum cleared of ramucirumab (IMC-1121B) per unit time] after a single dose of ramucirumab (IMC-1121B).
|
Cycle 1: Pre-infusion, Days 1, 2, 3, 5, 8, 12, and 15 of 28-day cycle
|
|
Ramucirumab Steady State Volume of Distribution (Vss) for Cycle 1
時間枠：Cycle 1: Pre-infusion, Days 1, 2, 3, 5, 8, 12, and 15 of 28-day cycle
|
Vss [distribution of ramucirumab (IMC-1121B) in the body at steady state] after a single dose of ramucirumab (IMC-1121B).
|
Cycle 1: Pre-infusion, Days 1, 2, 3, 5, 8, 12, and 15 of 28-day cycle
|
|
Ramucirumab Maximum Serum Concentration (Cmax) for Cycle 2
時間枠：Cycle 2: Pre-infusion, Days 1, 2, 3, 5, 8, 12, and 15 of 28-day cycle
|
Cmax after multiple doses of ramucirumab (IMC-1121B).
|
Cycle 2: Pre-infusion, Days 1, 2, 3, 5, 8, 12, and 15 of 28-day cycle
|
|
Ramucirumab Area Under the Concentration Time Curve (AUC) for Cycle 2
時間枠：Cycle 2: Pre-infusion, Days 1, 2, 3, 5, 8, 12, and 15 of 28-day cycle
|
AUC within the dosing interval (0-τ) after multiple doses of ramucirumab (IMC-1121B).
|
Cycle 2: Pre-infusion, Days 1, 2, 3, 5, 8, 12, and 15 of 28-day cycle
|
|
Ramucirumab Half-Life (t1/2) for Cycle 2
時間枠：Cycle 2: Pre-infusion, Days 1, 2, 3, 5, 8, 12, and 15 of 28-day cycle
|
Terminal t1/2 [the time it takes for the concentration of ramucirumab (IMC-1121B) in plasma or serum to decline by 50%] after multiple doses of ramucirumab(IMC-1121B).
|
Cycle 2: Pre-infusion, Days 1, 2, 3, 5, 8, 12, and 15 of 28-day cycle
|
|
Ramucirumab Clearance (CL) for Cycle 2
時間枠：Cycle 2: Pre-infusion, Days 1, 2, 3, 5, 8, 12, and 15 of 28-day cycle
|
CL [the volume of plasma or serum cleared of ramucirumab (IMC-1121B) per unit time] at steady state after multiple doses of ramucirumab (IMC-1121B).
|
Cycle 2: Pre-infusion, Days 1, 2, 3, 5, 8, 12, and 15 of 28-day cycle
|
|
Ramucirumab Steady State Volume of Distribution (Vss) for Cycle 2
時間枠：Cycle 2: Pre-infusion, Days 1, 2, 3, 5, 8, 12, and 15 of 28-day cycle
|
Vss [distribution of ramucirumab (IMC-1121B) in in the body at steady state] is not calculated for multiple doses of ramucirumab (IMC-1121B).
|
Cycle 2: Pre-infusion, Days 1, 2, 3, 5, 8, 12, and 15 of 28-day cycle
|
|
Ramucirumab Maximum Serum Concentration (Cmax) for Cycle 3
時間枠：Cycle 3: Pre-infusion, Day 1 of 28-day cycle
|
Due to sparse pharmacokinetic sampling ramucirumab (IMC-1121B) Cmax could not be calculated in Cycle 3.
|
Cycle 3: Pre-infusion, Day 1 of 28-day cycle
|
|
Ramucirumab Area Under the Concentration Time Curve (AUC) for Cycle 3
時間枠：Cycle 3: Pre-infusion, Day 1 of 28-day cycle
|
Due to the sparse pharmacokinetic sampling ramucirumab (IMC-1121B) AUC within the dosing interval (0-τ) could not be calculated in Cycle 3.
|
Cycle 3: Pre-infusion, Day 1 of 28-day cycle
|
|
Ramucirumab Half-Life (t 1/2) for Cycle 3
時間枠：Cycle 3: Pre-infusion, Day 1 of 28-day cycle
|
Due to sparse pharmacokinetic sampling ramucirumab (IMC-1121B) t1/2 could not be calculated in Cycle 3.
|
Cycle 3: Pre-infusion, Day 1 of 28-day cycle
|
|
Ramucirumab Clearance (CL) for Cycle 3
時間枠：Cycle 3: Pre-infusion, Day 1 of 28-day cycle
|
Due to sparse pharmacokinetic sampling CL could not be calculated for ramucirumab (IMC-1121B) in Cycle 3.
|
Cycle 3: Pre-infusion, Day 1 of 28-day cycle
|
|
Ramucirumab Steady State Volume of Distribution (Vss) for Cycle 3
時間枠：Cycle 3: Pre-infusion, Day 1 of 28-day cycle
|
Due to sparse pharmacokinetic sampling Vss for ramucirumab (IMC-1121B) could not be calculated in Cycle 3.
|
Cycle 3: Pre-infusion, Day 1 of 28-day cycle
|
|
Ramucirumab Maximum Serum Concentration (Cmax) for Cycle 4
時間枠：Cycle 4: Pre-infusion, Day 1 of 28-day cycle
|
Due to sparse pharmacokinetic sampling ramucirumab (IMC-1121B) Cmax could not be calculated in Cycle 4.
|
Cycle 4: Pre-infusion, Day 1 of 28-day cycle
|
|
Ramucirumab Area Under the Concentration Time Curve (AUC) for Cycle 4
時間枠：Cycle 4: Pre-infusion, Day 1 of 28-day cycle
|
Due to sparse pharmacokinetic sampling AUC within the dosing interval (0-τ) for ramucirumab (IMC-1121B) could not be calculated in Cycle 4.
|
Cycle 4: Pre-infusion, Day 1 of 28-day cycle
|
|
Ramucirumab Half-Life (t 1/2) for Cycle 4
時間枠：Cycle 4: Pre-infusion, Day 1 of 28-day cycle
|
Due to sparse pharmacokinetic sampling t1/2 for ramucirumab (IMC-1121B) could not be calculated in Cycle 4.
|
Cycle 4: Pre-infusion, Day 1 of 28-day cycle
|
|
Ramucirumab Clearance (CL) for Cycle 4
時間枠：Cycle 4: Pre-infusion, Day 1 of 28-day cycle
|
Due to sparse pharmacokinetic sampling CL for ramucirumab (IMC-1121B) could not be calculated in Cycle 4.
|
Cycle 4: Pre-infusion, Day 1 of 28-day cycle
|
|
Ramucirumab Steady State Volume of Distribution (Vss) for Cycle 4
時間枠：Cycle 4: Pre-infusion, Day 1 of 28-day cycle
|
Due to sparse pharmacokinetic sampling Vss for ramucirumab (IMC-1121B) could not be calculated in Cycle 4.
|
Cycle 4: Pre-infusion, Day 1 of 28-day cycle
|
協力者と研究者
ここでは、この調査に関係する人々や組織を見つけることができます。
スポンサー
出版物と役立つリンク
研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。
研究記録日
これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。
主要日程の研究
研究開始
2010年11月1日
一次修了 (実際)
2011年10月1日
研究の完了 (実際)
2011年10月1日
試験登録日
最初に提出
2010年12月2日
QC基準を満たした最初の提出物
2010年12月2日
最初の投稿 (見積もり)
2010年12月3日
学習記録の更新
投稿された最後の更新 (見積もり)
2014年6月18日
QC基準を満たした最後の更新が送信されました
2014年5月16日
最終確認日
2014年5月1日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- 14204
- CP12-1026 (その他の識別子：ImClone Systems)
- I4T-IE-JVBW (その他の識別子：Eli Lilly and Company)
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。